TY  - CHAP
M1  - Book, Section
TI  - Immunotherapy for Mesothelioma
A1  - Tano, Zachary E.
A1  - Dozier, Jordan
A1  - Vaghjiani, Raj G.
A1  - Adusumilli, Prasad S.
A2  - Sugarbaker, David J.
A2  - Bueno, Raphael
A2  - Burt, Bryan M.
A2  - Groth, Shawn S.
A2  - Loor, Gabriel
A2  - Wolf, Andrea S.
A2  - Williams, Marcia
A2  - Adams, Ann
Y1  - 2020
N1  - 
T2  - Sugarbaker’s Adult Chest Surgery, 3e
AB  - Utilizing  the  body’s  own  immune  responses  to  combat  malignancies  is  not  a  recent  phenomenon.  In  the  late  1880s,  Dr.  William  B.  Coley  utilized  staphylococcal  toxins  following  his  observation  of  tumor  regression  in  patients  who  had  been  exposed  to  infectious  pathogens.1  In  recent  years,  the  application  of  immunotherapy  has  evolved  to  include  many  different  biologic  facets  such  as  modulating  the  tumor  immune  microenvironment  (TME)  and  shifting  its  balance  toward  an  antitumor  state  (Fig.  121-1).  Current  immunotherapeutic  treatments  for  malignant  pleural  mesothelioma  (MPM)  involve  cell-  and  antibody-mediated  immunotherapies.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1170414092
ER  -